TheClinical Trials Dashboard is a resource for patients and physicians to find a current listing of open clinical trials. Clinical trials are essential to improving understanding of the disease and make progress against . We want to ensure patients and physicians have the most up-to-date information on clinical trials.
- Clinical Trials Infographic – This informative tool outlines the importance of clinical trials.
- To learn more about clinical trials, click here to view BCAN’s Patient Insight Webinars, featuring experts sharing the latest information about clinical trials.
The Dashboard organizes clinical trials by disease state to make it easier to find a trial that is a good match for each patient. In addition, this tool allows you to search specifically for clinical trials in your geographic area. Find the disease state that matches your situation and click on it to see the active clinical trials. If you have questions about a specific, click on the trial location and call or email the identified contact person.
The firstname.lastname@example.org if you have a trial to include in the listings.Clinical Trials Dashboard is a comprehensive listing of open clinical trials, but may not capture all current trials, especially those that are smaller in scope. The Dashboard will be updated quarterly, so please contact us at
The Dashboard is a collaborative effort of the members of the Clinical Trials Working Group at BCAN’s OncoGenex Pharmaceuticals, Inc.Think Tank. The Clinical Trials Dashboard is supported by a generous grant from
- Nonmuscle-Invasive Disease
Treatments for Nonmuscle-Invasive Urothelial Carcinoma
- Urothelial Bladder Cancer
The most common type of bladder cancer. Urothelial carcinomas are separated clinically into superficial tumors and muscle invasive tumors.
Use of immune checkpoint inhibitors to target molecules that serve as checks and balances in the regulation of immune responses. By blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are designed to unleash or enhance pre-existing anti-cancer immune responses.
- Muscle Invasive Disease
- Advanced/Metastatic Disease